Temporal Analysis of Tear Fluid Proteome Reveals Critical Corneal Repair Events After Photorefractive Surgery
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.13.49 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Nadege Feret and 9 co-authors. Institution: Institute for Neurosciences of Montpellier, University of Montpellier, INSERM, Montpellier, France. Major MEDLINE topics: Photorefractive Keratectomy, Tears, Proteome, Wound Healing. Cited 2 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To map time-resolved tear proteome changes during corneal epithelial wound healing after photorefractive keratectomy (PRK) and nominate tear-based biomarker panels with translational potential.
Methods
Tears from 10 healthy adults were collected before PRK (Pre), ∼30-60 minutes after PRK (D0), and day 3 (D3) using Schirmer strips. Proteins were extracted (SP3), trypsin-digested, and analyzed by DIA on an Evosep One-timsTOF HT platform. DIA-NN (1% FDR) provided identification/quantification. Paired contrasts (Pre vs. D0; Pre vs. D3) defined differentially abundant proteins (adjusted P 2.5) and UniProt-based annotation distinguished secreted versus intracellular candidates.
Results
Across 2025 identified proteins, 909 (∼45%) were significantly modulated. D0 tears showed an "injury/ECM" program (e.g., TGFBI, lumican, keratocan, fibrinogen chains, complement C8B, APOA1), whereas D3 shifted toward remodeling and epithelial polarity with regulated proteolysis (e.g., SERPINA3, MMP7, THBS1, MUC5B, CXCL17). A subset persisted across time points (e.g., A2M, haptoglobin, OLFML3). Intracellular signatures paralleled phase transitions: D0 was enriched for chromatin/DNA-repair and RNA-binding proteins (histones, XRCC5/Ku80, HNRNPs), whereas D3 highlighted transport/cytoskeletal factors linked to apical remodeling and fluid/ion handling (AQP5, NHERF1/EBP50, ANO1/TMEM16A, ACTN1, RDX). H6PD was elevated at both D0 and D3.
Conclusions
Time-stamped, tear-accessible biomarker panels emerge from this analysis: early-injury (TGFBI, lumican/keratocan, fibrinogen/complement), sustained (A2M, haptoglobin, OLFML3), and late-remodeling/epithelial (SERPINA3, MMP7, THBS1, MUC5B, CXCL17), with complementary intracellular markers (AQP5/NHERF1/ANO1). These candidates may support perioperative monitoring, risk stratification (delayed closure, stromal haze), and phase-adapted therapy after PRK, warranting prospective clinical validation.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Institute for Neurosciences of Montpellier, University of Montpellier, INSERM, Montpellier, France.
- Department of Ophthalmology, Gui de Chauliac Hospital, Montpellier, France.
- IRMB-PPC, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France.
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney NSW, Australia.
Cite
APA
Feret, N., Ter Schiphorst, S., Kindermans, J., Crowdy, H., Fichter, L., Vialaret, J., Hirtz, C., Loulier, K., Michon, F., & Daien, V. (2025). Temporal Analysis of Tear Fluid Proteome Reveals Critical Corneal Repair Events After Photorefractive Surgery. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.13.49
Vancouver
Feret N, Ter Schiphorst S, Kindermans J, Crowdy H, Fichter L, Vialaret J, et al. Temporal Analysis of Tear Fluid Proteome Reveals Critical Corneal Repair Events After Photorefractive Surgery. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.13.49
BibTeX
@article{Feret2025,
author = {Feret, Nadege and Ter Schiphorst, Solene and Kindermans, Jana and Crowdy, Hannah and Fichter, Laura and Vialaret, Jerome and Hirtz, Christophe and Loulier, Karine and Michon, Frederic and Daien, Vincent},
title = {Temporal Analysis of Tear Fluid Proteome Reveals Critical Corneal Repair Events After Photorefractive Surgery},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.13.49}
}
EUVIMED